Pharmacology of irbesartan

Bibliography

• MURRAY CJL, LOPEZ AD: Evidence-based health policy - lessons from the Global Burden of Disease study. Sci-ence (1996) 274:740–743.
   PubMed Web of Science ®Google Scholar
• BURT VL, WHELTON P, ROCCELLA EJ et al: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension (1995) 25:305–313.
   Google Scholar
• STOCKWELL DH, MADHAVAN S, COHEN H, GIBSON G, ALDERMAN MH: The determinants of hypertension awareness, treatment, and control in an insured popu-lation. Am. J. Public Health (1994) 84:1768–1774.
   PubMed Web of Science ®Google Scholar
• BRUNNER HR: The new angiotensin II receptor antago-nist, irbesartan: pharmacokinetic and pharmacody-namic considerations. Am. J. Hypertens. (1997) 10:311S–317S.
   Google Scholar
• JOINT NATIONAL COMMITTEE ON PREVENTION, DETEC-TION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE: The sixth report of the Joint National Com-mittee on Prevention, Detection, Evaluation, andTreatment of High Blood Pressure. Arch. Intern. Med.(1997) 157:2413–2446.
   PubMed Web of Science ®Google Scholar
• MCCOMBS JS, NICHOL MB, NEWMAN CM, SCLAR DA: The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med. Care (1994) 32:214–226.
   PubMed Web of Science ®Google Scholar
• CARO JJ, JACKSON J, SPECKMAN J, SALAS M, RAGGIO G: Compliance as a function of initial choice of antihy-pertensive drug. Am. J. Hypertens. (1997) 10 (2):141A. Ab-stract.
   Google Scholar
• TEERLINK JR: Neurohumoral mechanisms in heart fail-ure: a central role for the renin-angiotensin system. J. Cardiovasc. Pharmacol (1996) 27 (Suppl. 2):S1–S8.
   Google Scholar
• GAVRAS H, FAXON DP, BERKOBEN J, BRUNNER HR, RYAN TJ: Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation(1978) 58:770–776.
   PubMed Web of Science ®Google Scholar
• LONN EM, YUSUF S, JHA P et al.: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 90:2056–2068.
   PubMed Web of Science ®Google Scholar
• SIMON SR, BLACK HR, MOSER M, BERLAND WE: Coughand ACE inhibitors. Arch. Intern. Med. (1992) 152:1698–1700.
   PubMed Web of Science ®Google Scholar
• LACOURCIERE Y, BRUNNER H, IRWIN R et al.: Effects of modulators of the renin - angiotensin - aldosterone system on cough. J. Hypertens. (1994) 12:1387–1393.
   PubMed Web of Science ®Google Scholar
• POWELL JR, REEVES RA, MARINO MR, CAZAUBON C, NI-SATO D: A review of the new angiotensin II receptor antagonist irbesartan. Cardiovasc. Drug Rev. (1998). In press.
   Google Scholar
• CAZAUBON C, GOUGAT J, BOUSQUET F et al.: Pharma-cological characterization of SR 47436, a new nonpep-tide ATi subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. (1993) 265:826–834.
   PubMed Web of Science ®Google Scholar
• •This early paper provided the first report of the pharma-cologic characteristics of irbesartan, including its potent, se-lective, specific and insurmountable blockade of the ATi subtype of the angiotensin II receptor as demonstrated in in vivo and in vitro tests.
   Google Scholar
• HERBERT J-M, DELISEE C, DOL F et al.: Effect of SR 47436, a novel angiotensin II ATi receptor antagonist, on hu-man vascular smooth muscle cells in vitro. Eur. J. Phar-macol. (1994) 251:143–150.
   PubMed Web of Science ®Google Scholar
• JOHNSTON CI: Preclinical pharmacology of angio-tensin II receptor antagonists: update and outstanding issues. Am. J. Hypertens. (1997) 10:306S–310S.
   Google Scholar
• CHRISTOPHE B, LIBON R, CAZAUBON C, NISATO D, MANNING A, CHATELAIN P: Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II- induced pres-sor responses in the pithed rat: potential mechanisms of action. Eur.J. Pharmacol (1995) 281:161–171.
   PubMed Web of Science ®Google Scholar
• RIBSTEIN J, SISSMANN J, PICARD A, BOUROUDIAN M, MIMRAN A: Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exoge-nous angiotensin II and the renin- angiotensin system in sodium replete normal subjects. J. Hypertens. (1994) 12:131. Abstract.
   Google Scholar
• RIBSTEIN J, PICARD A, ARMAGNAC C, BOUROUDIAN M,SISSMANN J, MIMRAN A: Full antagonism of pressor re-sponse to exogenous angiotensin II (All) by single-dose irbesartan in normotensive subjects. J. Hypertens. (1997) 15 (Suppl. 4):S117. Abstract.
   Google Scholar
• BELZ GG, BUTZER R, MANG C, KOBER S, MUTSCHLER E: Greater extent and duration of the inhibitory effect of irbesartan on angiotensin II challenge in man com-pared to losartan and valsartan. Eur. J. Clin. Pharmacol (1998) 54:A8. Abstract.
   Google Scholar
• SISSMANN J, BOUROUDIAN M, ARMAGNAC C, DONA-ZOLLO Y, LATREILLE M, PANIS R: Angiotensin II block-ade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor an-tagonist SR 47436 (BMS 186295). J. Hypertens. (1994) 12:S92. Abstract.
   Google Scholar
• VACHHARAJANI N, CHANG S-Y, SHYU WC, GREENE D,BARBHAIYA R: Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist, in man. Pharm. Res. (1995) 12:S418. Abstract.
   Google Scholar
• VACHHARAJANI N, SHYU WC, MANTHA S, PARK J-S, GREENE D, BARBHAIYA R: Lack of food effect on the oral bioavailability of irbesartan. J. Clin. Pharmacol (1997) 37:872. Abstract.
   Google Scholar
• MARINO MR, LANGENBACHER KM, FORD NF, UDERMANHD: Safety, tolerability, pharmacokinetics and phar-macodynamics of irbesartan after single and multiple doses in healthy male subjects. Clin. Pharmacol. Ther. (1997) 61:207. Abstract.
   Google Scholar
• MARINO MR, LANGENBACHER KM, RAYMOND RH, FORDNF, DILZER S, LASSETER KC: Pharmacokinetics and pharmacodynamics of irbesartan in subjects with he-patic cirrhosis. J. Clin. Pharmacol. (1997) 37:871. Ab-stract.
   Google Scholar
• MARINO MR, LANGENBACHER KM, RAYMOND RH, FORDNF, LASSETER KC: Pharmacokinetics and pharmacody-namics of irbesartan in patients with hepatic cirrho-sis. J. Clin. Pharmacol. (1998) 38:347–356.
   PubMed Web of Science ®Google Scholar
• SICA DA, MARINO MR, HAMMETT JL, FERREIRA I, GEHRTWB, FORD NF: The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin. Pharmacol. Ther. (1997) 62:610–618.
   PubMed Web of Science ®Google Scholar
• VACHHARAJANI N, SHYU WC, GREENE D, BARBHAIYA R: The effect of age on the pharmacokinetics of irbesar-tan. J. Clin. Pharmacol (1997) 37:872. Abstract.
   Google Scholar
• VACHHARAJANI N, SHYU WC, SMITH R, CHANG S-Y, GREENED, BARBHAIYA R: The effects of age and gender on the pharmacokinetics of irbesartan. Pharm. Res. (1995) 12:S388. Abstract.
   Google Scholar
• MARINO MR, HAMMETT JL, FERREIRA I, FORD NF, UDER-MAN HD: Lack of effect of nifedipine on the pharma-cokinetics of irbesartan in healthy male subjects. J. Clin. Pharmacol. (1997) 37:872. Abstract.
   Google Scholar
• MARINO MR, HAMMETT JL, FERREIRA I, FORD NF, UDER- MAN HD Effect of nifedipine on the steady-state phar-macokinetics and pharmacodynamics of irbesartan ina healthy subjects. J. Cardiovasc. Pharmacol. Ther. (1998) 3:111–118.
   PubMedGoogle Scholar
• MARINO MR, LANGENBACHER KM, FORD NF et al.: Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbe-sartan. Clin. Drug Invest. (1997) 14:383–391.
   Web of Science ®Google Scholar
• GIELSDORF W, MANGOLD B, MARINO MR: Pharmacody-namics and pharmacokinetics of warfarin given with irbesartan. Clin. Pharmacol. Ther. (1998) 63:228. Abstract.
   Google Scholar
• POOL JL, GUTHRIE RM, LITTLEJOHN TW et al: Dose-related antihypertensive effects of irbesartan in pa-tients with mild-to-moderate hypertension. Am. J. Hy-pertens. (1998) 11:462–470.
   PubMed Web of Science ®Google Scholar
• GUTHRIE R, SAINT R, HERMAN T, PLESKOW W, SPRECHER D, COLLINS G: Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hy-pertension. A double-blind, placebo-controlled, dose-titration study. Clin. Drug Invest. (1998) 15:217–227.
   Web of Science ®Google Scholar
• REEVES RA, UN C-S, KASSLER-TAUB K, POULEUR H: Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension (1998) 31:1311–1316.
   PubMed Web of Science ®Google Scholar
• ••This analysis of pooled data from more than 2600 patientswith mild-to-moderate hypertension treated in eight ran-domised, placebo-controlled, double-blind studies demon-strated a clear relationship between irbesartan (log) dose and antihypertensive effect.
   Google Scholar
• FOGARI R, AMBROSOLI S, CORRADI L et al.: 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J. Hypertens. (1997) 15:1511–1518.
   PubMed Web of Science ®Google Scholar
• •This study utilised ambulatory blood pressure monitoring to demonstrate that irbesartan significantly reduces blood pressure for a full 24 h, thus establishing the appropriateness of a o.d. dosing regimen with irbesartan.
   Google Scholar
• WEIR MR, TOLCHIN N, TOTH P, REEVES RA: Addition of hydrochlorothiazide to irbesartan produces further dose-related reductions in blood pressure within two weeks. J. Hypertens. (1998) 16\(Suppl. 2):S130. Abstract.
   Google Scholar
• ROSENSTOCK J, ROSSI L, LIN CS, MACNEIL D, OSBAKKEN M: The efficacy and safety of irbesartan added to hydrochlorothiazide for the treatment of hyperten-sion in patients nonresponsive to hydrochlorothia-zide alone. J. Hypertens. (1997) 15 (Suppl. 4):S189. Abstract.
   Google Scholar
• WEBER M, SAINT R, KASSLER-TAUB K, REGGI D, FERDOUSI T, NALENCE A: Irbesartan combined with low-dose hydrochlorothiazide for mild-to-moderate hypertension. J. Hypertens. (1998) 16 (suppl. 2):S129.
   Google Scholar
• KOCHAR M, GUTHRIE R, TRISCARI J et al.: Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension. Am. J. Hypertens. (1997) 10 (2) :106A. Abstract.
   Google Scholar
• PHILLIPS P, HOWE P, GANDY M, MORAN S, KASSLER-TAUB K, SAINT R: Antihypertensive efficacy of the com-bination of irbesartan and hydrochlorothiazide as-sessed by 24-hour ambulatory blood pressure monitoring. J. Hypertens. (1997) 15 (suppl. 4):5181. Ab-stract.
   Google Scholar
• POULEUR HG: Clinical overview of irbesartan: a new angiotensin II receptor antagonist. Am. J. Hypertens. (1997) 10:318S–324S.
   Google Scholar
• LITTLEJOHN T, III, SAINT R, KASSLER-TAUB KB, CHRY-SANT SG, MARBURY T: Long-term safety and efficacy of irbesartan (up to 300mg) in hypertension. Am. J. Hyper-tens. (1998) 11 (suppl.):101A. Abstract.
   Google Scholar
• GUTHRIE R, FLACK J, ZUSMAN R, SAINT R, TRISCARI J: Long-term therapy with irbesartan and hydrochlo-rothiazide in hypertension. Am. J. Hypertens. (1998) 11 (suppl.):45A. Abstract.
   Google Scholar
• MIMRAN A, RUILOPE L, KERWIN L et al.: A randomised, double-blind comparison of the angiotensin II recep-tor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hyper-tension. J. Hum. Hypertens. (1998) 12:203–208.
   PubMed Web of Science ®Google Scholar
• LAROCHELLE P, FLACK JM, MARBURY TC, SARELI P, KRIEGER EM, REEVES RA: Effects and tolerability of irbe-sartan versus enalapril in patients with severe hyper-tension. Am. J. Cardiol. (1997) 80:1613–1615.
   PubMed Web of Science ®Google Scholar
• STUMPE KO, HAWORTH D, HOGLUND C et al.: Compari-son of the angiotensin II receptor antagonist irbesar-tan with atenolol for treatment of hypertension. Blood Press. (1998) 7:31–37.
   PubMedGoogle Scholar
• POHL M, COOPER M, ULREY J, PAULS J, ROHDE R: Safety and efficacy of irbesartan in hypertensive patients with Type II diabetes and proteinuria. Am. J. Hypertens. (1997) 10:105A. Abstract.
   Google Scholar
• KASSLER-TAUB K, LITTLEJOHN T, ELLIOTT W, RUDDY T, ADLER E: Comparative efficacy of two angiotensin II re-ceptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am. J. Hypertens. (1998) 11:445–453.
   PubMed Web of Science ®Google Scholar
• OPARIL S, GUTHRIE R, LEWIN AJ et al.: An elective-titration study on the comparative effectiveness of two angiotensin ffreceptor blockers, irbesartan and losar-tan. Clin. Ther. (1998) 20:398–409.
   PubMed Web of Science ®Google Scholar
• HAYAKAWA H, COFFEE K, GUERRA J, RAU L: Cardio-renal protection by the angiotensin II blocker irbesar-tan in salt sensitive hypertension. Am. J. Hypertens. (1997) 10:94A. Abstract.
   Google Scholar
• ZIAI F, OTS M, PROVOOST AP, TROY JL et al: The angio-tensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int. (1996) 50\(Supp1.57):5132–S136.
   Google Scholar
• MCCUNE SA, CARRAWAY JW, RADIN MJ, HOLYCROSS BJ: Comparison of irbesartan to captopril in heart failure prone male SHHF/MCC-FACE rats. J. Hypertens. (1996) 14 (Supp1.1) :S137. Abstract.
   Google Scholar
• PORUSH JG, BERL T, ANZALONE DA, ROHDE R: Multi-center collaborative trial of angiotensin II receptor an-tagonism on morbidity, mortality and renal function in hypertensive Type II diabetic patients with nephro-pathy. Am. J. Hypertens. (1998) 11 (Suppl.):73A. Abstract.
   Google Scholar
• KAHAN T, MALMQVIST K, EDNER M, HELD C, OSBAKKEN M: Rate and extent of left ventricular hypertrophy re-gression: a comparison of angiotensin II blockade with irbesartan and beta-blockade. JACC (1998) 31 (Suppl.C):258C. Abstract.
   Google Scholar
• HAVRANEK EP, THOMAS I, SMITH WB, PONCE G, BIL- SKER M, MUNGER M et al: Dose-related beneficial long-term hemodynamic and clinical effects of irbesartan in heart failure. Circulation (1997) 96 (Suppl.):1-452. Ab-stract.
   Google Scholar
• VIJAY N, ALHADDAD IA, DENNY DM et al.: Irbesartan compared with lisinopril in patients with mild to mod-erate heart failure. J. Am. Coll. Cardiol. (1998) 31 (suppLA):188A. Abstract.
   Google Scholar
• TONKON M, AWAN N, NIAZI I et al.: Evaluation of irbe-sartan in combination with conventional therapy, in-cluding angiotensin converting enzyme inhibitors, in heart failure. J. Am. Coll. Cardiol (1998) 31:188A. Abstract.
   Google Scholar
• SIMON TA, GELARDEN T, FREITAG SA, KASSLER-TAUB KB, DAVIES R: Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am. J. Car-diol. (1998) 82:179–182.
   PubMed Web of Science ®Google Scholar
• ••This analysis of data from nine randomised, placebo-controlled studies in more than 2600 patients with mild-to-moderate hypertension was critical to establishing the placebo-like safety and tolerability profile of irbesartan and its lack of dose-related adverse effects.
   Google Scholar
• JULIUS S: Current trends in the treatment of hyperten- sion: a mixed picture. Am. J. Hypertens. (1997) 10:300S-305S. Colin I Johnston University of Melbourne, Department of Medicine, Austin Campus, Heidelberg 3084, Victoria, Australia Tel.: +61 3 9496 5198; Fax: +61 3 9457 5485;
   Google Scholar